-
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
worldpharmanews
June 06, 2019
Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1].
-
FDA Approves First PI3K Inhibitor for Breast Cancer
americanpharmaceuticalreview
May 29, 2019
The U.S. Food and Drug Administration (FDA) has approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive ...
-
Scientists develop technique for better detection of breast cancer
biospectrumasia
May 29, 2019
Researchers at Okayama University report in the journal Sensors and Actuators B: Chemical that terahertz radiation can be used to rapidly detect makers for breast-cancer cells.
-
MSD’s Keytruda falls short in late stage breast cancer study
pharmatimes
May 21, 2019
MSD has announced that its anti-PD-1 therapy Keytruda has failed to meet its primary endpoint in a late-stage study testing the drug as a standalone treatment in patients with metastatic triple-negative breast cancer (TNBC).
-
NIR identifies breast cancer patients who will benefit from chemotherapy
europeanpharmaceuticalreview
April 29, 2019
Scientists have developed a new optical imaging system that uses red and near-infrared light (NIR) to identify breast cancer patients who will respond to chemotherapy.
-
New breast cancer blood test could help spot relapse two years earlier
pharmatimes
April 24, 2019
New research from Imperial College London and University of Leicester has found that a simple blood test could help to detect breast cancer relapse up to two years earlier than imaging in patients with early-stage breast cancer.
-
Intas launches trastuzumab biosimilar to treat breast cancer
firstwordpharma
April 11, 2019
Intas Pharmaceuticals announced Wednesday that it launched its trastuzumab biosimilar, under the brand name Eleftha, in India, reported Business Standard.
-
FDA approves Pfizer's Ibrance for advanced male breast cancer
pharmafile
April 11, 2019
FDA approves Pfizer's Ibrance for advanced male breast cancer.
-
FDA expands Ibrance’s label to include male breast cancer patients
pharmaceutical-technology
April 09, 2019
FDA expands Ibrance’s label to include male breast cancer patients
-
Pfizer uses real-world data to score Ibrance breast cancer nod in males
fiercepharma
April 08, 2019
Breast cancer is a rare disease in men, making it tough for drugmakers to conduct clinical trials. But Pfizer came up with a solution.